| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | January 30, 2023 |
| Accession Number: | 0001437749-23-001936 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)
SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)
SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tipsPURSUIT clinical trial completion expected by year-endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / November 10, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today reported financial results for the quarter ended September 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the third quarter of 2022, we continued to make great progress in the final phase of our pivotal U.S. PURSUIT clinical trial fo
ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its third quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 10, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The third quarter 2022 results conference call may be accessed on Thursday, November 10th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://event.choruscall.com/mediaframe/we
Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tipsPURSUIT clinical trial follow-up visit completion anticipated by year endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / August 11, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today reported financial results for the quarter ended June 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the second quarter of 2022, we continued to advance our stress urinary incontinence (SUI) clinical development program. We
15-12G - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
Alliance Global Partners initiated coverage of Viveve Medical with a rating of Buy
Alliance Global Partners initiated coverage of Viveve Medical with a rating of Buy and set a new price target of $10.75
Gainers Ontrak (NASDAQ:OTRK) stock increased by 44.3% to $0.83 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.4 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 25.55% to $6.19. The market value of their outstanding shares is at $246.0 million. Tricida (NASDAQ:TCDA) stock moved upwards by 21.81% to $0.16. The market value of their outstanding shares is at $9.3 million. Avenue Therapeutics (NASDAQ:ATXI) stock increased by 18.59% to $2.36. The market value of their outstanding shares is at $11.2 million. Sigilon Therapeutics (NASDAQ:SGTX) shares moved upwards by 14.89% to $0.47. The market value of their outstanding shares
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Tuesday. The Dow traded down 0.87% to 34,003.26 while the NASDAQ rose 0.25% to 11,106.50. The S&P 500 also rose, gaining, 0.01% to 3,999.18. Check This Out: Global Crypto Market Cap Hits $1 Trillion; Gala, Casper Among Top Gainers Leading and Lagging Sectors Energy shares gained by 0.3% on Tuesday. Meanwhile, top gainers in the sector included HighPeak Energy, Inc. (NASDAQ:HPK), up 9%, and Vertex Energy, Inc. (NASDAQ:VTNR), up 8%. In trading on Tuesday, communication services shares fell by 1.3%. Top Headline Morgan Stanley reported better-than-expected Q4 results. Morgan Stanl
Gainers Celyad Oncology SA (NASDAQ:CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211. Calyxt, Inc. (NASDAQ:CLXT) gained 116% to $0.4014 after the company and Cibus announced a definitive merger agreement. BIT Mining Limited (NYSE:BTCM) shares climbed 34.5% to $4.13 after the company announced the launch of a new energy efficient LiteCoin/DogeCoin Miner, LD3. Aligos Therapeutics, Inc. (NASDAQ:ALGS) jumped 29.9% to $2.13 after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $3 to $7. Neovasc Inc. (NASDAQ:NVCN) surged 29.5% to
Study's primary efficacy endpoint was not achieved at 12 months post-treatmentCompany has implemented a reduction in forceCompany will seek strategic alternatives and will be delisted from Nasdaq ENGLEWOOD, CO / ACCESSWIRE / January 17, 2023 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced topline result from the U.S. Pivotal PURSUIT clinical trial. PURSUIT was a multicenter, randomized, double-blinded, sham-controlled U.S. study to evaluate the safety and efficacy of the Viveve treatment for SUI in women. The results were obtained by the company on Friday evening, Janu
Topline results of the 12-month primary efficacy endpoint anticipated in January 2023Positive results may support a de novo marketing application for a new U.S. indication for treatment of stress urinary incontinence in womenENGLEWOOD, CO / ACCESSWIRE / December 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and treatment of female stress urinary incontinence, today announced the completion of final 12-month post-treatment follow-up visits in its landmark U.S. PURSUIT clinical trial for the treatment of stress urinary incontinence (SUI) in women. A total of 415 patients were enrolled in the trial, and 342 patients completed 12-month foll
Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trialENGLEWOOD, CO / ACCESSWIRE / December 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11511110 covering Viveve's treatment to address SUI in women. The issuance of the new patent strengthens the Company's intellectual property portfolio in advance of the planned completion of its U.S. pivotal PURSUIT clinical trial by the e